Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and it’s most ambitious yet This study builds on the HYPER-H21-1 and HYPER-H21-2 findings, as well as the HYPER-H21-3 study that is set to begin dosing in mid-November 2021 Lexaria’s goal is to pursue regulatory approval for its proprietary DehydraTECH-CBD for potential use … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4”
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs for 2022. According to the update, the studies mentioned in the announcement represent only a fraction of Lexaria’s 2022 work programs. “Calendar 2022 will continue to see significant milestones in utilizing … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes”
Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to FDA-approved seizure drug, Epidiolex The study will also compare DehydraTECH-CBD to generic CBD EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3 2022 Lexaria received new … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio”
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition, the company provided updates on three ongoing human clinical studies evaluating its proprietary DehydraTECH-CBD for potentially treating hypertension and heart disease. “HYPER-H21-4 is the most ambitious study Lexaria has … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date”
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1,designed to evaluate whether its DehydraTECH(TM)-CBD (“CBD”) indicates superior ability to reduce seizure activity compared to both generic cannabidiol and Epidiolex. Epidiolex is the only CBD medication approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex”
Lexaria Bioscience Corp. (NASDAQ: LEXX) was recently part of coverage by Zacks Small-Cap Research analysts based on its market potential. Zacks, which focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators, valued the company at … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses”
Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology It showed that the technology required a shorter time to deliver the same THC levels than concentration-matched controls Lexaria believes that through DehydraTECH, it is meeting the needs of medical THC users with its rapid delivery, increased overall THC delivery and high … Continue reading “Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users”
Oral drug delivery innovator Lexaria Bioscience is focused on providing alternatives to smoked or inhaled tobacco and cannabis products to help consumers reduce the threat to their lungs Lexaria’s patented technology — DehydraTECH(TM) — is a solution that processes active pharmaceutical ingredients into a powder or liquid form that can then be ingested with less … Continue reading “New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology as an Alternative to Smoking and Vaping”
Lexaria Bioscience (NASDAQ: LEXX), developers of the revolutionary DehydraTECH(TM) drug-delivery technology, has released study results focused on THC-A21-1, a THC oral format. According to the announcement, the study showed that Lexaria’s DehydraTECH THC solution delivers THC levels to blood plasma an estimated three times faster than standard MCT-based THC. Based on study results, it took only … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Reveals Effectiveness of Proprietary Drug-Development Tech”
Lexaria’s recent animal study on its patented DehydraTECH(TM) technology on nicotine absorption yielded ground-breaking results This study builds on an earlier 2018 study that demonstrated effective delivery of nicotine to the central nervous system in a rodent study The study’s success will serve as the foundation for a human trial that will compare the DehydraTECH-nicotine … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery”
